Antabio Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 25

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $29.1M

  • Investors
  • 12

Antabio General Information

Description

Operator of a privately-held clinical-stage biopharmaceutical company intended for novel and differentiated antibacterial treatments of drug-resistant infections. The company's focus is on critical priority pathogens, with a particular focus on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases, enabling health professionals to get access to medicinal products that help in curing drug-resistant diseases.

Contact Information

Website
www.antabio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 436, Rue Pierre et Marie Curie
  • 31670 Labege
  • France
+33 05
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 436, Rue Pierre et Marie Curie
  • 31670 Labege
  • France
+33 05

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Antabio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series B) 28-Nov-2023 $29.1M Completed Clinical Trials - Phase 1
8. Grant 15-Jun-2022 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series A) 06-Apr-2022 Completed Pre-Clinical Trials
6. Grant 01-Dec-2021 Completed Pre-Clinical Trials
5. Later Stage VC (Series A) 12-Jul-2018 Completed Pre-Clinical Trials
4. Grant 25-Jul-2017 Completed Pre-Clinical Trials
3. Seed Round 31-Dec-2015 Completed Product In Beta Test
2. Grant 01-Jan-2015 $4.91M Completed Product In Beta Test
1. Grant 01-Jan-2013 $6.17M Completed Product In Beta Test
To view Antabio’s complete valuation and funding history, request access »

Antabio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A2 Shares
Ordinary
A2 Shares
Ordinary
Ordinary 4,440 $1.100521 $247.87 $247.87 1x $247.87 6.24%
Ordinary 3,021 $1.100521 $182.1 $182.1 1x $182.1 4.25%
To view Antabio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Antabio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a privately-held clinical-stage biopharmaceutical company intended for novel and differentiated antibacteria
Drug Discovery
Labege, France
25 As of 2025

Berlin, Germany
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Antabio Competitors (7)

One of Antabio’s 7 competitors is TME Pharma, a Formerly VC-backed company based in Berlin, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TME Pharma Formerly VC-backed Berlin, Germany
Spero Therapeutics Formerly VC-backed Cambridge, MA
AiCuris Formerly VC-backed Wuppertal, Germany
Genfit Formerly VC-backed Loos, France
Innate Pharma Formerly VC-backed Marseille, France
You’re viewing 5 of 7 competitors. Get the full list »

Antabio Patents

Antabio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025215253-A1 Dosing regimen comprising (2r,5r)-2-fluoro-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulphate and a beta-lactam antibiotic Pending 12-Apr-2024
EP-4125883-A1 Combination therapy Inactive 24-Mar-2020
US-20240016941-A1 Combination therapy Inactive 24-Mar-2020
WO-2021191240-A1 Combination therapy Inactive 24-Mar-2020
EP-3670512-A1 Diazabicyclooctanones as inhibitors of serine beta-lactamases Inactive 18-Dec-2018 C07D471/08
To view Antabio’s complete patent history, request access »

Antabio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Antabio Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
AMR Action Fund Impact Investing Minority
Relyens Impact Investing Minority
European Innovation Council Accelerator/Incubator Minority
Bpifrance Sovereign Wealth Fund Minority
BNP Paribas Développement PE/Buyout Minority
You’re viewing 5 of 12 investors. Get the full list »

Antabio FAQs

  • When was Antabio founded?

    Antabio was founded in 2009.

  • Where is Antabio headquartered?

    Antabio is headquartered in Labege, France.

  • What is the size of Antabio?

    Antabio has 25 total employees.

  • What industry is Antabio in?

    Antabio’s primary industry is Drug Discovery.

  • Is Antabio a private or public company?

    Antabio is a Private company.

  • What is Antabio’s current revenue?

    The current revenue for Antabio is .

  • How much funding has Antabio raised over time?

    Antabio has raised $62.5M.

  • Who are Antabio’s investors?

    AMR Action Fund, Relyens, European Innovation Council, Bpifrance, and BNP Paribas Développement are 5 of 12 investors who have invested in Antabio.

  • Who are Antabio’s competitors?

    TME Pharma, Spero Therapeutics, AiCuris, Genfit, and Innate Pharma are some of the 7 competitors of Antabio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process